{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:54Z","timestamp":1790957634167,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DMSO"],"DOI":"10.2147\/dmso.s212715","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T23:29:53Z","timestamp":1562110193000},"page":"1001-1012","source":"Crossref","is-referenced-by-count":25,"title":["<p>SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions<\/p>"],"prefix":"10.2147","volume":"Volume 12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-8449","authenticated-orcid":true,"given":"Naser Eddin","family":"Gharaibeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5191-9867","authenticated-orcid":true,"given":"Marie-Noel","family":"Rahhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,7]]},"container-title":["Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=50936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=50936","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T23:29:53Z","timestamp":1562110193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/sglt-2-inhibitors-as-promising-therapeutics-for-non-alcoholic-fatty-li-peer-reviewed-article-DMSO"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dmso.s212715","relation":{},"ISSN":["1178-7007"],"issn-type":[{"value":"1178-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}